Find Research outputs

Search results

• Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

  Abaza, Y., Kantarjian, H., Alwash, Y., Borthakur, G., Champlin, R., Kadia, T., Garcia-Manero, G., Daver, N., Ravandi, F., Verstovsek, S., Burger, J., Estrov, Z., Ohanian, M., Lim, M., Pemmaraju, N., Jabbour, E. & Cortes, J., Nov 1 2020, In: American Journal of Hematology. 95, 11, p. 1288-1295 8 p.

  Research output: Contribution to journal › Article › peer-review
  9 Scopus citations

• Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

  Ravandi, F., Cortes, J. E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M. Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S. R., Brandt, M., Byrd, A., Bekele, B. N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H. M., Apr 10 2010, In: Journal of Clinical Oncology. 28, 11, p. 1856-1862 7 p.

  Research output: Contribution to journal › Article › peer-review
  301 Scopus citations

• Phase diagram of two-component dipolar fermions in one-dimensional optical lattices

  De Silva, T. N., May 3 2013, In: Physics Letters, Section A: General, Atomic and Solid State Physics. 377, 12, p. 871-877 7 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Phase diagram of strongly attractive p-orbital fermions on optical lattices

  De Silva, T. N., Oct 30 2015, In: Physics Letters, Section A: General, Atomic and Solid State Physics. 379, 42, p. 2715-2722 8 p., 23378.

  Research output: Contribution to journal › Article › peer-review

• Phase Changes in a Leucite‐Containing Dental Porcelain Frit

  Rodway Mackert, J., Butts, M. B., Morena, R. & Fairhurst, C. W., Apr 1986, In: Journal of the American Ceramic Society. 69, 4, p. C‐69-C‐72

  Research output: Contribution to journal › Article › peer-review
  38 Scopus citations

• Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study

  Cortes, J., Gammon, G., Khaled, S., Martinelli, G., Kramer, A., Steffen, B., Hogge, D., Jonas, B. A., Dombret, H. & Perl, A., Oct 1 2016, In: Annals of Oncology. 27, p. vi327

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up

  Kantarjian, H., Cortes, J., Kim, D. W., Dorlhiac-Llacer, P., Pasquini, R., DiPersio, J., Müller, M. C., Radich, J. P., Khoury, H. J., Khoroshko, N., Bradley-Garelik, M. B., Zhu, C. & Tallman, M. S., 2009, In: Blood. 113, 25, p. 6322-6329 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  145 Scopus citations

• Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

  Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E., Pigneux, A., Horst, H. A., Récher, C., Klimek, V. M., Cortes, J. E., Carella, A. M., Egyed, M., Krug, U., Fox, J. A., Craig, A. R., Ward, R. & 4 others, Smith, J. A., Acton, G., Kantarjian, H. M. & Stuart, R. K., Oct 31 2018, In: Haematologica. 103, 11, p. e514-e518

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  7 Scopus citations

• Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

  Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R., Solomon, S. R., Kolitz, J. E., Cooper, M., Yeager, A. M., Louie, A. C. & Feldman, E. J., May 22 2014, In: Blood. 123, 21, p. 3239-3246 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  239 Scopus citations

• Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

  Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Faderl, S., Ferrajoli, A., Borthakur, G., George, S., Scherle, P. A., Newton, R. C., Kantarjian, H. M. & Ravandi, F., May 17 2012, In: Blood. 119, 20, p. 4614-4618 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  152 Scopus citations

• Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

  Cortes, J., Digumarti, R., Parikh, P. M., Wetzler, M., Lipton, J. H., Hochhaus, A., Craig, A. R., Benichou, A. C., Nicolini, F. E. & Kantarjian, H. M., May 2013, In: American Journal of Hematology. 88, 5, p. 350-354 5 p.

  Research output: Contribution to journal › Article › peer-review
  50 Scopus citations

• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

  Cortes, J., Lipton, J. H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A. C., Craig, A. R., Michallet, M., Nicolini, F. E. & Kantarjian, H., Sep 27 2012, In: Blood. 120, 13, p. 2573-2580 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  110 Scopus citations

• Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission

  Abou Dalle, I., Kantarjian, H. M., Ravandi, F., Daver, N., Wang, X., Jabbour, E., Estrov, Z., DiNardo, C. D., Pemmaraju, N., Ferrajoli, A., Jain, N., Wang, S. A., Jammal, N., Borthakur, G., Naqvi, K., Pelletier, S., Pierce, S., Andreeff, M., Garcia-Manero, G., Cortes, J. E. & 1 others, Kadia, T. M., Jun 1 2021, In: Cancer. 127, 11, p. 1894-1900 7 p.

  Research output: Contribution to journal › Article › peer-review

• Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

  Sasaki, K., Kantarjian, H., Wierda, W., Ravandi-Kashani, F., Jorgensen, J., Wang, S. A., Khoury, J., Daver, N., Burger, J., Di Nardo, C. D., Jain, N., Short, N. J., Estrov MD, Z., Konopleva MD, PhD, M., Ohanian DO, M., Garcia-Manero, G., Kadia, T., Alvarado-Valero, Y., Yilmaz, M., Pierce, S. & 5 others, Garris, R., Ingram, A., Cortes, J., OʼBrien, S. & Jabbour, E., Jul 1 2020, In: American Journal of Hematology. 95, 7, p. 734-739 6 p.

  Research output: Contribution to journal › Article › peer-review
  5 Scopus citations

• Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

  Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J. & Verstovsek, S., Feb 11 2010, In: Blood. 115, 6, p. 1131-1136 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  183 Scopus citations

• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

  Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., Nazha, A., Konopleva, M., Borthakur, G., Burger, J., Kadia, T., Dellasala, S., Andreeff, M., Cortes, J., Kantarjian, H. & Levis, M., Jun 6 2013, In: Blood. 121, 23, p. 4655-4662 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  277 Scopus citations

• Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

  Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R. & Wetzler, M., Jan 15 2012, In: Cancer. 118, 2, p. 418-427 10 p.

  Research output: Contribution to journal › Article › peer-review
  22 Scopus citations

• Phase 2 clinical trial of rapamycin-resistant donor CD4⁺ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

  Fowler, D. H., Mossoba, M. E., Steinberg, S. M., Halverson, D. C., Stroncek, D., Khuu, H. M., Hakim, F. T., Castiello, L., Sabatino, M., Leitman, S. F., Mariotti, J., Gea-Banacloche, J. C., Sportes, C., Hardy, N. M., Hickstein, D. D., Pavletic, S. Z., Rowley, S., Goy, A., Donato, M., Korngold, R. & 5 others, Pecora, A., Levine, B. L., June, C. H., Gress, R. E. & Bishop, M. R., Apr 11 2013, In: Blood. 121, 15, p. 2864-2874 11 p.

  Research output: Contribution to journal › Article › peer-review
  24 Scopus citations

• Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

  Kantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O'Brien, S., Jeha, S., Davis, J., Shaked, Z., Craig, A., Keating, M., Plunkett, W. & Freireich, E. J., Oct 1 2003, In: Blood. 102, 7, p. 2379-2386 8 p.

  Research output: Contribution to journal › Article › peer-review
  264 Scopus citations

• Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

  Cortes, J. E., Tallman, M. S., Schiller, G. J., Trone, D., Gammon, G., Goldberg, S. L., Perl, A. E., Marie, J. P., Martinelli, G., Kantarjian, H. M. & Levis, M. J., Aug 9 2018, In: Blood. 132, 6, p. 598-607 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  81 Scopus citations

• Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

  Krause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M. & Henkel, T., Jun 2004, In: Antimicrobial agents and chemotherapy. 48, 6, p. 2021-2024 4 p.

  Research output: Contribution to journal › Article › peer-review
  151 Scopus citations

• Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

  Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T. Y. A., Janik, J. E., Fleisher, T. A., Albert, P. S., Figg, W. D., Spencer, S. D., Raffeld, M., Decker, J. R., Goldman, C. K., Bryant, B. R., Petrus, M. N., Creekmore, S. P. & Morris, J. C., Jul 17 2013, In: Blood. 121, 3, p. 476-484 9 p.

  Research output: Contribution to journal › Article › peer-review
  44 Scopus citations

• Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

  Borthakur, G., Alvarado, Y., Ravandi-Kashani, F., Cortes, J., Estrov, Z., Faderl, S., Ivy, P., Bueso-Ramos, C., Bekele, B. N. & Giles, F., Jul 15 2008, In: Cancer. 113, 2, p. 360-366 7 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

  Cortes, J., Quintás-Cardama, A., Garcia-Manero, G., O'Brien, S., Jones, D., Faderl, S., Ebarb, T., Giles, F., Thomas, D. & Kantarjian, H., Nov 1 2007, In: Cancer. 110, 9, p. 2000-2006 7 p.

  Research output: Contribution to journal › Article › peer-review
  36 Scopus citations

• Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

  Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., Bonfils, C., Dubay, M., Patterson, T. A., Li, Z., Besterman, J. M., Reid, G., Laille, E., Martell, R. E. & Minden, M., Aug 15 2008, In: Blood. 112, 4, p. 981-989 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  218 Scopus citations

• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

  Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V. R., Randolph, S. S., Hardwick, J. S., Reilly, J. F., Chen, C., Ricker, J. L., Secrist, J. P., Richon, V. M., Frankel, S. R. & 1 others, Kantarjian, H. M., 2008, In: Blood. 111, 3, p. 1060-1066 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  388 Scopus citations

• Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

  Altman, J. K., Foran, J. M., Pratz, K. W., Trone, D., Cortes, J. E. & Tallman, M. S., Feb 2018, In: American Journal of Hematology. 93, 2, p. 213-221 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  49 Scopus citations

• Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

  Roboz, G. J., Giles, F. J., List, A. F., Cortes, J. E., Carlin, R., Kowalski, M., Bilic, S., Masson, E., Rosamilia, M., Schuster, M. W., Laurent, D. & Feldman, E. J., Jun 2006, In: Leukemia. 20, 6, p. 952-957 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  75 Scopus citations

• Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia

  Talpaz, M., O'Brien, S., Rose, E., Gupta, S., Shan, J., Cortes, J., Giles, F. J., Faderl, S. & Kantarjian, H. M., Sep 15 2001, In: Blood. 98, 6, p. 1708-1713 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  70 Scopus citations

• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

  Issa, J. P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J. & Kantarjian, H. M., Mar 1 2004, In: Blood. 103, 5, p. 1635-1640 6 p.

  Research output: Contribution to journal › Article › peer-review
  696 Scopus citations

• Phase 1 study of Lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

  Cortes, J., Jabbour, E., Daley, G. Q., O'Brien, S., Verstovsek, S., Ferrajoli, A., Koller, C., Zhu, Y., Statkevich, P. & Kantarjian, H., Sep 15 2007, In: Cancer. 110, 6, p. 1295-1302 8 p.

  Research output: Contribution to journal › Article › peer-review
  48 Scopus citations

• Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

  Kantarjian, H., Le Coutre, P., Cortes, J., Pinilla-Ibarz, J., Nagler, A., Hochhaus, A., Kimura, S. & Ottmann, O., Jun 1 2010, In: Cancer. 116, 11, p. 2665-2672 8 p.

  Research output: Contribution to journal › Article › peer-review
  47 Scopus citations

• Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

  Lee, J. H., Faderl, S., Pagel, J. M., Jung, C. W., Yoon, S. S., Pardanani, A. D., Becker, P. S., Lee, H., Choi, J., Lee, K., Kim, M. & Cortes, J. E., May 12 2020, In: Blood Advances. 4, 9, p. 2032-2043 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  15 Scopus citations

• Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

  Borthakur, G., Zeng, Z., Cortes, J. E., Chen, H. C., Huang, X., Konopleva, M., Ravandi, F., Kadia, T., Patel, K. P., Daver, N., Kelly, M. A., McQueen, T., Wang, R. Y., Kantarjian, H. & Andreeff, M., Nov 1 2020, In: American Journal of Hematology. 95, 11, p. 1296-1303 8 p.

  Research output: Contribution to journal › Article › peer-review
  6 Scopus citations

• Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

  Borthakur, G., Rosenblum, M. G., Talpaz, M., Daver, N., Ravandi, F., Faderl, S., Freireich, E. J., Kadia, T., Garcia-Manero, G., Kantarjian, H. & Cortes, J. E., Feb 1 2013, In: Haematologica. 98, 2, p. 217-221 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  48 Scopus citations

• Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

  Yee, K. W. L., Hagey, A., Verstovsek, S., Cortes, J., Garcia-Manero, G., O'Brien, S. M., Faderl, S., Thomas, D., Wierda, W., Kornblau, S., Ferrajoli, A., Albitar, M., McKeegan, E., Grimm, D. R., Mueller, T., Holley-Shanks, R. R., Sahelijo, L., Gordon, G. B., Kantarjian, H. M. & Giles, F. J., Sep 15 2005, In: Clinical Cancer Research. 11, 18, p. 6615-6624 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  75 Scopus citations

• Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

  Cortes, J., Talpaz, M., Smith, H. P., Snyder, D. S., Khoury, J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R., Mitchell, D., Wise, S. C., Rutkoski, T. J., Smith, B. D., Flynn, D. L., Kantarjian, H. M., Rosen, O. & Van Etten, R. A., Feb 28 2017, In: Haematologica. 102, 3, p. 519-528 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  15 Scopus citations

• Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia

  Cortes, J., Podoltsev, N., Kantarjian, H., Borthakur, G., Zeidan, A. M., Stahl, M., Taube, T., Fagan, N., Rajeswari, S. & Uy, G. L., Jan 2021, In: International Journal of Hematology. 113, 1, p. 92-99 8 p.

  Research output: Contribution to journal › Article › peer-review
  5 Scopus citations

• Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

  Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'Brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E. & Issa, J. P., Nov 15 2006, In: Blood. 108, 10, p. 3271-3279 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  437 Scopus citations

• Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

  Halwani, A. S., Panizo, C., Isufi, I., Herrera, A. F., Okada, C. Y., Cull, E. H., Kis, B., Chaves, J. M., Bartlett, N. L., Ai, W., de la Cruz-Merino, L., Bryan, L. J., Houot, R., Linton, K., Briones, J., Chau, I., von Keudell, G. R., Lu, H., Yakovich, A., Chen, M. & 4 others, Meulen, J. H. T., Yurasov, S., Hsu, F. J. & Flowers, C. R., 2021, (Accepted/In press) In: Leukemia and Lymphoma.

  Research output: Contribution to journal › Article › peer-review

• Pharyngitis

  Brown, J. J. & Ho, B., May 28 2015, The 5-Minute Clinical Consult Standard 2016: Twenty Fourth Edition. Wolters Kluwer Health Adis (ESP)

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

• Pharyngeal Swallowing Mechanics Secondary to Hemispheric Stroke

  May, N. H., Pisegna, J. M., Marchina, S., Langmore, S. E., Kumar, S. & Pearson, W. G., May 2017, In: Journal of Stroke and Cerebrovascular Diseases. 26, 5, p. 952-961 10 p.

  Research output: Contribution to journal › Article › peer-review
  16 Scopus citations

• Pharmacy practice research: Understanding health-related quality of life

  MacKinnon, N. J. & Chaudhary, D. A. N., 1999, In: Canadian Pharmaceutical Journal. 132, 10, p. 33-34 2 p.

  Research output: Contribution to journal › Article › peer-review

• Pharmacy practice research: Pharmacoeconomics and decision analysis for community pharmacists

  MacKinnon, G. E. & MacKinnon, N. J., 2000, In: Canadian Pharmaceutical Journal. 133, 8, p. 28-30 3 p.

  Research output: Contribution to journal › Short survey › peer-review

• Pharmacy practice research: An introduction to disease-specific health-related quality of life instruments

  Chaudhary, D. A. N. & MacKinnon, N. J., 2000, In: Canadian Pharmaceutical Journal. 133, 6, p. 40-44 5 p.

  Research output: Contribution to journal › Review article › peer-review

• Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients

  Hogarty, G. E., McEvoy, J. P., Ulrich, R. F., DiBarry, A. L., Bartone, P., Cooley, S., Hammill, K., Carter, M., Munetz, M. R. & Perel, J., Jan 1995, In: Archives of General Psychiatry. 52, 1, p. 29-41 13 p.

  Research output: Contribution to journal › Article › peer-review
  76 Scopus citations

• Pharmacotherapy of delusional disorders in the context of offending and the potential for compulsory treatment

  Smith, D. A. & Buckley, P. F., Jul 21 2006, In: Behavioral Sciences and the Law. 24, 3, p. 351-367 17 p.

  Research output: Contribution to journal › Review article › peer-review
  12 Scopus citations

• Pharmacotherapy for treatment-refractory schizophrenia

  Van Sant, S. P. & Buckley, P. F., Feb 2011, In: Expert Opinion on Pharmacotherapy. 12, 3, p. 411-434 24 p.

  Research output: Contribution to journal › Review article › peer-review
  20 Scopus citations

• Pharmacophore-based discovery of new human dihydroorotate dehydrogenase inhibitor

  Lu, P., Wang, Y., Ma, B., She, J., Zhang, Q., He, M. & Liu, Y., Jun 2014, In: Medicinal Chemistry. 10, 4, p. 402-408 7 p.

  Research output: Contribution to journal › Article › peer-review
  3 Scopus citations

• Pharmacomimetics of exercise: Novel approaches for hippocampally-targeted neuroprotective agents

  Stranahan, A. M., Zhou, Y., Martin, B. & Maudsley, S., 2009, In: Current Medicinal Chemistry. 16, 35, p. 4668-4678 11 p.

  Research output: Contribution to journal › Review article › peer-review
  59 Scopus citations